Eli Lilly (the company behind Mounjaro and Zepbound) just announced impressive phase 3 clinical trial results for a new weight loss medication, orforglipron, a GLP-1. Experts say that the drug has a ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Health and Human Services Secretary Robert F. Kennedy Jr.'s announcement that the federal government will cancel nearly $500 million in mRNA research funding is unnerving not only for those who ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks and benefited from reductions in bad cholesterol, blood fats and blood pressure.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

UnitedHealthcare says it’s dropping some of its Medicare Advantage plans that collectively cover 600,000 people.